Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre

INTRODUCTION Focal liver lesions (FLLs) are common on conventional ultrasound. Contrast-enhanced ultrasound (CEUS) is highly accurate for differentiating between benign and malignant FLLs, with an accuracy comparable to that of contrast-enhanced CT and contrast-enhanced MRI. Notably, the...

Full description

Bibliographic Details
Main Authors: Mikael Sawatzki, Christa Meyenberger, Stephan Brand, David Semela
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2019-06-01
Series:Swiss Medical Weekly
Subjects:
Online Access:https://www.smw.ch/index.php/smw/article/view/2634
_version_ 1797979653235802112
author Mikael Sawatzki
Christa Meyenberger
Stephan Brand
David Semela
author_facet Mikael Sawatzki
Christa Meyenberger
Stephan Brand
David Semela
author_sort Mikael Sawatzki
collection DOAJ
description INTRODUCTION Focal liver lesions (FLLs) are common on conventional ultrasound. Contrast-enhanced ultrasound (CEUS) is highly accurate for differentiating between benign and malignant FLLs, with an accuracy comparable to that of contrast-enhanced CT and contrast-enhanced MRI. Notably, there is no evidence supporting the routine use of CEUS for evaluating benign and malignant FLLs in Switzerland. In this study, we assessed the use of CEUS in a clinical routine setting in a tertiary Swiss gastroenterology centre. METHODS We analysed all CEUS investigations performed on new or unclear FLLs in our department between November 2011 and March 2013. In all patients, the CEUS results (benign versus malignant FLLs) were compared with CT or MRI findings. To avoid interobserver variation, CEUS was performed by a single experienced gastroenterologist using one ultrasound device (Acuson Sequoia 512®, Siemens, Erlangen, Germany). All patients were examined using the intravenous application of 1.5–2 ml Sonovue®. An FLL with arterial enhancement with wash-out in any vascular phase was defined as a malignant FLL. Malignant FLLs were confirmed by histology. RESULTS The study included 112 patients. None of them experienced side effects after injection of Sonovue®. The final diagnoses included malignant FLLs (n = 37) and benign FLLs (n = 75) that ranged in size from 7 to 120 mm. The biopsy-proven malignant FLLs (n = 37) included hepatocellular carcinoma, metastatic cancers, peripheral cholangiocarcinoma and primary B-cell lymphoma. CEUS correctly identified 36 out of 37 malignant FLLs, showing a sensitivity of 96–97.2% and a negative predictive value (NPV) of 94.1–98.5%. In contrast, CT/MRI did not identify three metastatic cancers, one HCC, one peripheral cholangiocarcinoma and one primary B-cell lymphoma in the liver as malignant FLLs, resulting in a sensitivity of 80.6–80.9% and an NPV of 78.9–89.8%. All these malignant FLLs were correctly classified by CEUS. CONCLUSIONS In daily clinical practice, CEUS is a fast imaging tool which uses a renal-independent contrast agent and shows excellent accuracy for differentiating between malignant and benign FLLs in about five minutes. The use of CEUS helps to avoid false negative results from CT/MRI and improves sensitivity. CEUS should be the first diagnostic step for investigating new or unclear FLLs.
first_indexed 2024-04-11T05:43:07Z
format Article
id doaj.art-24e92c499b8c42738e7b92a1d990fd9b
institution Directory Open Access Journal
issn 1424-3997
language English
last_indexed 2024-04-11T05:43:07Z
publishDate 2019-06-01
publisher SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
record_format Article
series Swiss Medical Weekly
spelling doaj.art-24e92c499b8c42738e7b92a1d990fd9b2022-12-22T04:42:22ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972019-06-01149252610.4414/smw.2019.20087Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centreMikael SawatzkiChrista MeyenbergerStephan BrandDavid Semela INTRODUCTION Focal liver lesions (FLLs) are common on conventional ultrasound. Contrast-enhanced ultrasound (CEUS) is highly accurate for differentiating between benign and malignant FLLs, with an accuracy comparable to that of contrast-enhanced CT and contrast-enhanced MRI. Notably, there is no evidence supporting the routine use of CEUS for evaluating benign and malignant FLLs in Switzerland. In this study, we assessed the use of CEUS in a clinical routine setting in a tertiary Swiss gastroenterology centre. METHODS We analysed all CEUS investigations performed on new or unclear FLLs in our department between November 2011 and March 2013. In all patients, the CEUS results (benign versus malignant FLLs) were compared with CT or MRI findings. To avoid interobserver variation, CEUS was performed by a single experienced gastroenterologist using one ultrasound device (Acuson Sequoia 512®, Siemens, Erlangen, Germany). All patients were examined using the intravenous application of 1.5–2 ml Sonovue®. An FLL with arterial enhancement with wash-out in any vascular phase was defined as a malignant FLL. Malignant FLLs were confirmed by histology. RESULTS The study included 112 patients. None of them experienced side effects after injection of Sonovue®. The final diagnoses included malignant FLLs (n = 37) and benign FLLs (n = 75) that ranged in size from 7 to 120 mm. The biopsy-proven malignant FLLs (n = 37) included hepatocellular carcinoma, metastatic cancers, peripheral cholangiocarcinoma and primary B-cell lymphoma. CEUS correctly identified 36 out of 37 malignant FLLs, showing a sensitivity of 96–97.2% and a negative predictive value (NPV) of 94.1–98.5%. In contrast, CT/MRI did not identify three metastatic cancers, one HCC, one peripheral cholangiocarcinoma and one primary B-cell lymphoma in the liver as malignant FLLs, resulting in a sensitivity of 80.6–80.9% and an NPV of 78.9–89.8%. All these malignant FLLs were correctly classified by CEUS. CONCLUSIONS In daily clinical practice, CEUS is a fast imaging tool which uses a renal-independent contrast agent and shows excellent accuracy for differentiating between malignant and benign FLLs in about five minutes. The use of CEUS helps to avoid false negative results from CT/MRI and improves sensitivity. CEUS should be the first diagnostic step for investigating new or unclear FLLs. https://www.smw.ch/index.php/smw/article/view/2634benign liver tumourblood pooled contrast agentcontrast-enhanced ultrasounddifferentiationfocal liver lesionhemangioma
spellingShingle Mikael Sawatzki
Christa Meyenberger
Stephan Brand
David Semela
Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre
Swiss Medical Weekly
benign liver tumour
blood pooled contrast agent
contrast-enhanced ultrasound
differentiation
focal liver lesion
hemangioma
title Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre
title_full Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre
title_fullStr Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre
title_full_unstemmed Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre
title_short Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre
title_sort contrast enhanced ultrasound ceus has excellent diagnostic accuracy in differentiating focal liver lesions results from a swiss tertiary gastroenterological centre
topic benign liver tumour
blood pooled contrast agent
contrast-enhanced ultrasound
differentiation
focal liver lesion
hemangioma
url https://www.smw.ch/index.php/smw/article/view/2634
work_keys_str_mv AT mikaelsawatzki contrastenhancedultrasoundceushasexcellentdiagnosticaccuracyindifferentiatingfocalliverlesionsresultsfromaswisstertiarygastroenterologicalcentre
AT christameyenberger contrastenhancedultrasoundceushasexcellentdiagnosticaccuracyindifferentiatingfocalliverlesionsresultsfromaswisstertiarygastroenterologicalcentre
AT stephanbrand contrastenhancedultrasoundceushasexcellentdiagnosticaccuracyindifferentiatingfocalliverlesionsresultsfromaswisstertiarygastroenterologicalcentre
AT davidsemela contrastenhancedultrasoundceushasexcellentdiagnosticaccuracyindifferentiatingfocalliverlesionsresultsfromaswisstertiarygastroenterologicalcentre